SCHEMBL5149757

SCHEMBL5149757

COC(=O)c1ccc(OC(C)NCC(=O)Cc2ccc(NC(=O)Nc3ccccc3C)c(OC)c2)c([N+](=O)[O-])c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGA4 P13612 6/20 0.46
▸ ITGB1 P05556 5/20 0.46
▸ ALDH1A1 P00352 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 4/20 0.40
▸ POLB P06746 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ AR P10275 1/20 0.40
▸ PELP1 Q8IZL8 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ AGTR1 P30556 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155691 0.92 KMT2A (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL5156914 0.91 MAPT (0.49) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5150075 0.88 ITGA4 (0.48) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5152817 0.88 ITGA4 (0.50) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5152225 0.87 ITGA4 (0.47) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5153145 0.86 ITGA4 (0.47) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5156366 0.86 KMT2A (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL5150243 0.86 ITGA4 (0.51) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5149694 0.85 ITGA4 (0.46) ITGA4ITGB1ALDH1A1MEN1KMT2A
SCHEMBL5149750 0.85 ALDH1A1 (0.43) ITGA4ITGB1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 ITGA4 4/4885ITGB1 8/4885ALDH1A1 120/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 ITGA4 5/4885ITGB1 7/4885ALDH1A1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback